Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Enclomifene (Primary) ; Testosterone
- Indications Hypogonadism
- Focus Registrational; Therapeutic Use
- Sponsors Repros Therapeutics
- 04 Apr 2016 Results assessing diurnal variation of testosterone secretion from four studies presented at The 98th Annual Meeting of the Endocrine Society
- 23 Oct 2015 Pooled results (ZA-304 + 305) published in the BJU International
- 01 Apr 2015 According to a Repros Therapeutics media release, US FDA accepted the New Drug Application for Enclomiphene Citrate developed for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.